COCP Financials 07/16/2014 08:05:51 Cocrystal Pha
Post# of 50
Cocrystal Pharma, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue - - 12,605 15,254
Cost of Revenue - - 9,920 8,428
Gross Profit - - 2,686 6,826
Operating Expenses
Research and Development 17 489 423 241
Sales, General and Admin. 3,283 2,064 6,149 6,617
Non-Recurring Items - - - -
Other - - - -
Operating Income (3,301) (2,553) (3,887) (32)
Income From Continuing Operations
Add'l Income/Expense Items (4,997) 154 (282) -
Earnings Before Interest and Tax (8,298) (2,400) (4,211) 23
Interest Expense 3,342 5,231 1,243 439
Earnings Before Tax (11,640) (7,631) (5,454) (416)
Income Tax - - 3 (96)
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - (43) 55
Net Income Cont. Operations (11,640) (7,631) (5,500) (265)
Non Recurring Events
Discontinued Operations (7,982) (333) - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (19,622) (7,965) (5,457) (320)
Preferred Stock and Other Adjustments (4,136) - - -
Net Income Applicable to Common Shareholders (23,758) (7,965) (5,457) (320)